Vitamin A (retinoids) regulation of mouse melanoma growth and differentiation

Richard M Niles1

  • 1Department of Biochemistry and Molecular Biology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25704, USA. niles@marshall.edu

The Journal of Nutrition
|January 7, 2003
PubMed

Insights

Retinoic acid (RA) induces melanoma cell growth arrest and differentiation. Protein kinase C (PKC)alpha is crucial for these RA effects, potentially through non-enzymatic mechanisms, offering new therapeutic avenues for invasive melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Melanoma incidence is rising, with limited effective chemotherapy options.
  • Retinoic acid (RA) shows potential for inducing growth arrest and differentiation in melanoma cells.
  • Understanding RA's molecular targets is key to developing new melanoma treatments.

Purpose of the Study:

  • To investigate the role of T-box binding protein-2 (Tbx-2) and protein kinase C (PKC)alpha in RA-mediated melanoma cell responses.
  • To elucidate the signaling pathways involved in RA-induced growth arrest and differentiation in B16 melanoma cells.

Main Methods:

  • Gene array analysis to identify RA-responsive genes.
  • Reporter assays to study RA response elements in the Tbx-2 promoter.
  • Western blotting to assess PKCalpha protein levels.
  • Dominant-negative gene expression to inhibit AP-1 activity.
  • Enzyme activity assays for PKC.

Main Results:

  • Tbx-2 was identified as a direct RA target gene with an RA response element in its promoter.
  • RA significantly increased PKCalpha RNA and protein levels in B16 melanoma cells.
  • RA-induced AP-1 activity occurred with delayed kinetics compared to phorbol dibutyrate.
  • Inhibition of PKC enzyme activity did not affect RA-induced AP-1 activity, growth inhibition, or melanin synthesis.

Conclusions:

  • PKCalpha is essential for RA's biological effects in melanoma cells, but likely acts through non-enzymatic mechanisms.
  • These findings suggest novel therapeutic strategies targeting PKCalpha's non-enzymatic functions in melanoma treatment.